Endogenous bradykinin and B1-B5 during angiotensin-converting enzyme inhibitor-associated angioedema. Hubers SA, Kohm K, Wei S, Yu C, Nian H, Grabert R, Sexton DJ, Brown NJ (2018) J Allergy Clin Immunol 142: 1636-1639.e5 Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. Brown NJ, Agirbasli MA, Williams GH, Litchfield WR, Vaughan DE (1998) Hypertension 32: 965-71 Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans. Brown NJ, Agirbasli M, Vaughan DE (1999) Hypertension 34: 285-90 Selective stimulation of tissue-type plasminogen activator (t-PA) in vivo by infusion of bradykinin. Brown NJ, Nadeau JH, Vaughan DE (1997) Thromb Haemost 77: 522-5 A randomized trial of a 6-week course of celecoxib on proteinuria in diabetic kidney disease. Sinsakul M, Sika M, Rodby R, Middleton J, Shyr Y, Chen H, Han E, Lehrich R, Clyne S, Schulman G, Harris R, Lewis J (2007) Am J Kidney Dis 50: 946-51 Inhibition of aminopeptidase P potentiates wheal response to bradykinin in angiotensin-converting enzyme inhibitor-treated humans. Kim KS, Kumar S, Simmons WH, Brown NJ (2000) J Pharmacol Exp Ther 292: 295-8
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.